Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain.
Cathepsin S inhibitors are well-known to be an attractive target as immunological therapeutic agents. Recently, our gene expression analysis identified that cathepsin S inhibitors could also be effective for neuropathic pain. Herein, we describe the efficacy of selective cathepsin S inhibitors as antihyperalgesics in a model of neuropathic pain in rats after oral administration.
Irie
Osamu
O
Novartis Institutes for BioMedical Research, Ohkubo 8, Tsukuba, Ibaraki 300-2611, Japan. osamu.irie@novartis.com.
Kosaka
Takatoshi
T
Ehara
Takeru
T
Yokokawa
Fumiaki
F
Kanazawa
Takanori
T
Hirao
Hajime
H
Iwasaki
Astuko
A
Sakaki
Junichi
J
Teno
Naoki
N
Hitomi
Yuko
Y
Iwasaki
Genji
G
Fukaya
Hiroaki
H
Nonomura
Kazuhiko
K
Tanabe
Keiko
K
Koizumi
Shinichi
S
Uchiyama
Noriko
N
Bevan
Stuart J
SJ
Malcangio
Marzia
M
Gentry
Clive
C
Fox
Alyson J
AJ
Yaqoob
Mohammed
M
Culshaw
Andrew J
AJ
Allan Hallett